Latest Health News

AGUIA RESOURCES LTD posted a $1.31 million net cash outflow for the December 2024 quarter, driven by exploration and evaluation expenses, while preparing for underground operations at its Santa Barbara Mine.

Reedy Lagoon Corporation reports promising soil sampling results at its Burracoppin Gold project while seeking partners for its iron venture amid challenging market conditions.

Po Valley Energy Limited reports a robust December 2024 quarter marked by rising gas production, strong revenue growth, and significant progress in exploration and development across its Italian assets.

HeraMED reports a surge in its HeraCARE platform users and secures $4.1 million in new funding, underpinning its expansion in the US maternity care market and integration with major health systems.

dorsaVi reported a modest 1.9% rise in sales revenue to $330k in Q2 FY25, launched its AI-powered Video AI movement analysis platform, and initiated a blockchain integration partnership to enhance data security.

Comet Ridge has made significant strides in its Mahalo Gas Hub development, approving upstream FEED and progressing pipeline connections, supported by a strong cash position of $19.3 million. These developments position the company to address Australia's tightening east coast gas market.

Careteq Limited reports solid progress in integrating its Embedded Health Solutions with HMR Referrals, alongside a 14% revenue increase and improved cash flow in Q2 FY25.

Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.

Ecofibre Limited reports a mixed financial performance for Q2 2025, highlighting significant debt reduction efforts and strategic restructuring to return to positive cash flows.

Hartshead Resources reports a robust December quarter with strategic progress on UK gas developments, fiscal clarity from government levy changes, and the acquisition of new licenses boosting its resource base.

Eden Innovations Ltd reports a striking 158% increase in US OptiBlend® sales for Q2 FY25, alongside expanding international traction for its EdenCrete® products and strategic property sales aimed at debt reduction.

Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.